Referred to the House Committee on Energy and Commerce.
Amends the Public Health Service Act (42 U.S.C. 290ee–2(f)) to reauthorize and increase authorized funding for grants for building communities of recovery, replacing prior $5,000,000 per year (FY2019–2023) with $17,000,000 per year for fiscal years 2026 through 2030.
Adequacy of the $17M annual authorization versus actual need
Relative to its intended legislative type, this bill is a narrowly scoped statutory amendment that replaces prior authorized-appropriation figures with new annual authorization levels for an existing grant program.
Amends the Public Health Service Act (42 U.S.C. 290ee–2(f)) to reauthorize and increase authorized funding for grants for building communities of recovery, replacing prior $5,000,000 per year (FY2019–2023) with $17,000,000 per year for fiscal years 2026 through 2030.
Small, technical reauthorization of popular recovery grants with modest cost and low controversy; success still depends on appropriations and legislative scheduling.
Relative to its intended legislative type, this bill is a narrowly scoped statutory amendment that replaces prior authorized-appropriation figures with new annual authorization levels for an existing grant program. It is precise in identifying the statutory provision to be amended and the exact numerical change, but it provides minimal contextual, fiscal analysis, or accountability detail beyond specifying the authorization amount and years.
Adequacy of the $17M annual authorization versus actual need
These are examples from the analysis, not a ranked list of the most-affected groups.
Adequacy of the $17M annual authorization versus actual need
Likely supportive: the bill raises federal investment in community recovery supports for people with substance use disorders.
Seen as a targeted, public-health approach to addiction that can expand services and equity.
Generally favorable but pragmatic: welcomes continuity and larger authorization while wanting clear oversight, measurable outcomes, and cost transparency.
Views as a modest, non-controversial health program expansion.
Cautiously skeptical: some support for treatment-focused funding, but concerns about expanding federal spending, program scope, and potential support for controversial harm-reduction models.
Prefers state control and evidence-based limits.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Small, technical reauthorization of popular recovery grants with modest cost and low controversy; success still depends on appropriations and legislative scheduling.
The bill has not accumulated any surfaced votes yet.
Adequacy of the $17M annual authorization versus actual need
Small, technical reauthorization of popular recovery grants with modest cost and low controversy; success still depends on appropriations a…
Relative to its intended legislative type, this bill is a narrowly scoped statutory amendment that replaces prior authorized-appropriation figures with new annual authorization levels for an existing grant program. It i…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.